68 filings
Page 3 of 4
8-K
6i4qem5
6 Jan 21
Entry into a Material Definitive Agreement
4:31pm
8-K
mwt o1t3jl9oeljiq
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
8-K
k86rhs
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
f6nh 9bc7u8p4
5 Nov 20
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:31am
8-K
rrqfn x5h7khf
14 Oct 20
Other Events
7:00am
8-K
kjhhzg
4 Aug 20
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
4:47pm
8-K
o2xndrw
30 Jun 20
Departure of Directors or Certain Officers
5:01pm
8-K
gv4l1n5l1lec6z8
11 Jun 20
Departure of Directors or Certain Officers
5:00pm
8-K
bo0bsfd
5 Jun 20
Departure of Directors or Certain Officers
5:26pm
8-K
k3efe65s 2wryjk
4 Jun 20
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
e635b 7pxy1ua
29 May 20
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTACĀ® Protein Degrader
7:06am
8-K
y95tpam07h3bg4ve8ic
14 May 20
Other Events
12:00am
8-K
cao5cxp8nidd7i0 pf
28 Apr 20
Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update
4:59pm
8-K
dc37c 6zt0c2
16 Mar 20
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
9:01am
8-K
m7o e9vx8
6 Feb 20
Entry into a Material Definitive Agreement
5:01pm
8-K
65jqfut5tuszr0e6z
21 Nov 19
Departure of Directors or Certain Officers
4:10pm
8-K
zam15b
12 Nov 19
Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
4:02pm
8-K
nlnew0qsw6
4 Nov 19
Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
5:10pm
8-K
oan z3p69
23 Oct 19
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTACĀ® Targeted Protein Degraders
6:39am
8-K
ydse37ai12hf
5 Aug 19
Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update
4:05pm